Further development of optical imaging technology for cancer research is now possible, thanks to $15 million in funding recently awarded to OnTarget Labs.

Based at the Purdue University Research Park, OnTarget received the funding from the Pension Fund of the Christian Church and from Tom Hurvis, original investor in the company and founder of Old World Industries.

The technology and research was developed by Philip Low, a chemistry professor and director of the Center for Drug Discovery at Purdue University, and co-founder of OnTarget. It is based on the over-expression of specific receptors on solid cancers.

The funding will also enable further clinical trials necessary for optimizing the technology platform.

For more information, visit: www.ontargetlabs.com.